In Practise Logo
In Practise Logo - Blue

Explore our full content library.

Lonza vs WuXi Biologics: BIOSECURE Act & U.S. Manufacturing Strategy

Partner Interview
Lonza Group•CH•Large CapCharles River Laboratories InternationalWuXi BiologicsCatalentThermo Fisher ScientificDanaherSwitching CostsMission Critical Products & Services
Feb 12, 2026

AGC Biologics & Western vs Chinese CDMOs

Partner Interview
AGC BiologicsWuXi BiologicsBayerLonza GroupThermo Fisher ScientificSartorius Stedim BiotechMerckPfizerCatalentSwitching CostsMission Critical Products & Services
Sep 19, 2025

Aldevron: mRNA, Plasmids and Synthetic DNA

IP Icon
IP Interview
Danaher•US•Large CapCatalentThermo Fisher ScientificModernaGenscript Biotech CorporationLonza GroupSwitching CostsMission Critical Products & Services
Jul 30, 2025

Lonza: CDMO Market Capacity

Partner Interview
Lonza Group•CH•Large CapCatalentSartorius Stedim BiotechAbbVieAvid BioservicesDanaherThermo Fisher ScientificCharles River Laboratories InternationalSwitching CostsMission Critical Products & Services
Jan 20, 2025

Danaher vs Thermo Fisher: Plasmid Manufacturing & Gene Therapy Positioning

IP Icon
IP Interview
Danaher•US•Large CapThermo Fisher ScientificLonza GroupCatalentCharles River Laboratories InternationalTwist BioscienceSwitching CostsMission Critical Products & Services
Jan 14, 2025

Danaher: Aldevron & DNA Plasmid Manufacturing

IP Icon
IP Interview
Danaher•US•Large CapSartoriusThermo Fisher ScientificCatalentLonza GroupSwitching CostsOEMs w/ Installed Base
Dec 16, 2024

Lifecore Biomedical: Customer Mix, Switching Cost & Power in the CDMO Value Chain

Partner Interview
Landec•US•Small CapNovo NordiskLonza GroupCatalent
Oct 6, 2024

You've reached the end